HIV-Infection Reduction-Rates in Patients, on Antiretroviral Efficacy-Trial of a Nigerian Broad-Spectrum Antiviral Medicine (Antivirt<sup>®</sup>)
- 1 College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria
- 2 Nigerian Institute of Medical Research, Lagos, Nigeria
- 3 College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria
- 4 Nigerian Institute of Medical Research, Lagos, Nigeria
- 5 Nigerian Institute of Medical Research, Lagos, Nigeria
- 6 Nigerian Institute of Medical Research, Lagos, Nigeria
- 7 College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria
- 8 College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria
- 9 College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria
- 10 College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria
- 11 College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria
- 12 College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria
Abstract
In verifying antiretroviral efficacy of a Nigerian broad spectrum antiviral medicine (Antivirt <sup>®</sup> ), the Nigerian Institute of Medical Research certified it safe by toxicological test on laboratory animals, before commencing treatment of three HIV/AIDS patients whose viral loads varied widely (millions, hundreds of thousands and thousands). To overcome errors associated with such wide differences in subject-classes, percentages of viral load-reductions were calculated instead of comparing their viral loads. After first month of the Antivirt <sup>®</sup> -treatment, means of ranked viral loads of the patients significantly (P ≤ 0.05) increased from 10.00 ± 7.21 to 11.30 ± 5.51 (-41.03% infection-reduction rate) instead of reducing. From second month of the trial, their viral loads started to reduce, continuously, so that their infection-reduction rates have been increasing from that -41.03%, to -38.22% in the second month; 23.98% in the third month; 31.76% in the fourth month and 64.12% after the fifth month.
- Ezeibe, M.C.O. and Ogbonna, I.J. (2015) Acquired Immune Deficiency Syndrome in Man and Animals—A Review. World Journal of Aids, 5, 50-57. https://doi.org/10.4236/wja.2015.51006
- HIV/AIDS: Where Did HIV Come from? http://www.infoplease.com/cig/dangerous-diseases-epidemics/hiv-origins.html#ixzz3OcwXMs00
- Brooks, G.F. (1998) Medical Microbiology. 21st Edition, McGraw Hill, San Francisco.
- Chen, B.D., Le, W.J., Wang, Y.L., Li, Z.Q., Wang, D., Ren, L., Lin, L., Cui, S.B., Hu,J.J., Hu, Y.H., Yang, P.Y., Ewing, R.C., Shi, D.L. and Cui, Z. (2016) Targeting Negative Surface Charges of Cancer Cells by Multifunctional Nanoprobes. Theranostics, 6, 1887-1898. https://doi.org/10.7150/thno.16358
- Cristina, E., Ivan, P. and Kevin, R. (2007) Nanomaterials and Nanoparticles: Sources and Toxicity. Biointerphases, 2, MR17-MR71. https://doi.org/10.1116/1.2815690
- Vanderbilt, R.T. (2012) Veegum—The Versatile Ingredient for Pharmaceutical Formulations. Inc. Technical Literature.
- Suni, L., Hiroaki, H., Megumi, M., Hidenori, M., Aoko, K.T., Ying, C., Kozo, U., Masayasu, K., Yasumitsu, N. and Takemi, O.T. (2014) Immunostimulation by Silica Particles and the Development of Autoimmune Dysregulation. InTechOpen, London.
- Ezeibe, M.C.O. (2012) Medicinal Synthetic Aluminum-Magnesium Silicate (Nanoparticles)—Antiviral Agent and Adjuvant to Chemotherapeutics. Federal Republic of Nigeria Patents and Designs Ref No. NG/P/2012/639.
- Murray, K.R. (2000) Harpers Biochemistry. McGraw Hill, New York.
- Ezeibe, M.C.O. and Ogbonna, I.J. (2016) Use of the Medicinal Synthetic Aluminum Magnesium Silicate to Enhance Efficacy of Antimicrobials, for Prevention and Treatment of Resistant Infections. 2nd International Conference and Exhibition on Pharmacology and Ethnopharmacology, Chicago, 2-4 May 2016.
- Ezeibe, M.C.O. (2017) Antivirt ® . Broad Spectrum Antiviral Medicine and Antiretroviral Medicine. Federal Republic of Nigeria Patents and Designs Ref No: NG/P/2017/2418.
- Steve Haltiwanger MD., CCN. (2011) The Electrical Properties of Cancer Cells. http://www.royalrife.com/haltiwanger1
- Gentile, M., Adrian, T., Scheidler, A., Ewald, M., Dianzani, F., Pauli, G. and Gelderblon, H.R. (1994) Determination of the Size of HIV Using Adenovirus Type 2 as an Internal Length Marker. Journal of Virological Methods, 4, 43-52. https://doi.org/10.1016/0166-0934(94)90087-6